tradingkey.logo

MaxCyte Inc

MXCT
View Detailed Chart
1.470USD
-0.200-11.98%
Close 11/06, 16:00ETQuotes delayed by 15 min
156.69MMarket Cap
LossP/E TTM

MaxCyte Inc

1.470
-0.200-11.98%
Intraday
1m
30m
1h
D
W
M
D

Today

-11.98%

5 Days

-2.65%

1 Month

-10.91%

6 Months

-44.74%

Year to Date

-64.66%

1 Year

-62.11%

View Detailed Chart

TradingKey Stock Score of MaxCyte Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

MaxCyte Inc's Score

Industry at a Glance

Industry Ranking
96 / 210
Overall Ranking
229 / 4615
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
6.344
Target Price
+279.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

MaxCyte Inc Highlights

StrengthsRisks
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Growing
The company is in a growing phase, with the latest annual income totaling USD 38.63M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 38.63M.
Overvalued
The company’s latest PE is -3.47, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 81.96M shares, decreasing 18.01% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 8.51K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.71.

MaxCyte Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

MaxCyte Inc Info

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Ticker SymbolMXCT
CompanyMaxCyte Inc
CEOMr. Maher Masoud, J.D.
Websitehttps://www.maxcyte.com/
KeyAI